MigVax 101
Alternative Names: MigVax-101Latest Information Update: 14 Jun 2022
Price :
$50 *
At a glance
- Originator MigVax
- Class COVID-19 vaccines; Protein vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 07 Jun 2022 Catalent and MigVax enters into a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology to deliver MigVax 101
- 10 Jun 2021 Preclinical trials in COVID-2019 infections (Prevention) in Israel (PO), before June 2021
- 09 Jun 2021 MigVax intends to commercialise MigVax 101 for COVID-2019 infections